GH Research executive files initial share holdings
GH Research PLC executive Halle Magnus Clemensen, Managing Director for Ireland, filed an initial ownership report showing direct holdings of 118,354 Ordinary Shares.
Rhea-AI Filing Summary
GH Research PLC executive Halle Magnus Clemensen, Managing Director for Ireland, filed an initial ownership report showing direct holdings of 118,354 Ordinary Shares. He also holds three grants of Share Options (Right to Buy) over 17,500, 150,000 and 50,000 underlying Ordinary Shares, each with an exercise price of 0.0250 per share and expirations in 2030, 2031 and 2032, respectively. For these options, 25% vests on specified initial dates, with the remainder vesting in equal monthly installments over three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Halle Magnus Clemensen
Role
Managing Director, Ireland
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Options (Right to Buy) — 217,500 contracts (Direct);
Ordinary Shares — 118,354 shares (Direct)
Footnotes (3)
- F1. The share options vested as to 25% on April 27, 2024, and the remaining share options vest in equal monthly installments for three years thereafter.
- F2. The share options vested as to 25% on November 25, 2025, and the remaining share options vest in equal monthly installments for three years thereafter.
- F3. The share options vest as to 25% on May 16, 2026, and the remaining share options vest in equal monthly installments for three years thereafter.
Key Figures
Ordinary Shares held: 118,354 shares
Option grant 1 underlying shares: 17,500 shares
Option grant 2 underlying shares: 150,000 shares
+3 more
6 metrics
Ordinary Shares held
118,354 shares
Direct ownership following reported holdings
Option grant 1 underlying shares
17,500 shares
Share Options (Right to Buy), expire on 2030-04-27
Option grant 2 underlying shares
150,000 shares
Share Options (Right to Buy), expire on 2031-11-25
Option grant 3 underlying shares
50,000 shares
Share Options (Right to Buy), expire on 2032-05-16
Option exercise price
0.0250 per share
Exercise price for all reported share options
Initial vesting portion
25%
Portion of each option grant vesting on its initial vesting date
Key Terms
Share Options (Right to Buy), Ordinary Shares, exercise price, vesting, +1 more
5 terms
exercise price financial
"conversion_or_exercise_price of 0.0250 per share for the options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"share options vested as to 25% and remaining options vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"option expiration dates on 2030-04-27, 2031-11-25 and 2032-05-16"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does GHRS Form 3 show about Halle Magnus Clemensen’s holdings?
The Form 3 shows Halle Magnus Clemensen directly holds 118,354 Ordinary Shares of GH Research PLC. It also reports several share option grants giving him the right to buy additional Ordinary Shares at a fixed exercise price of 0.0250 per share.
Are the GHRS holdings on this Form 3 direct or indirect for Halle Magnus Clemensen?
The Form 3 classifies all reported positions as direct ownership. Both the 118,354 Ordinary Shares and the three share option grants are listed with direct ownership type, indicating they are held in Clemensen’s own name rather than through another entity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
